v3.26.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Schedule of Segment Reporting The following table represents information provided to the CODM:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2026202520262025
Research and development expenses:
Wages and benefits$3,558 $1,940 $9,383 $5,200 
Tibulizumab SSc program2,741 3,054 10,149 7,251 
Tibulizumab HS program3,913 2,657 13,302 5,931 
Tibulizumab PMR program2,161 — 2,665 — 
Tibulizumab program general5,025 2,726 14,379 8,597 
Additional product candidates (torudokimab and crebankitug)265 481 615 1,231 
Unallocated research and development expenses596 521 1,636 1,454 
General and administrative expenses:
Wages and benefits2,257 2,450 6,936 7,832 
Other general and administrative expenses2,921 3,299 9,694 9,550 
Share-based compensation5,316 2,379 14,781 9,755 
Other segment items*(2,928)(1,467)(7,188)(5,326)
Net loss$25,825 $18,040 $76,352 $51,475 
*Other segment items include depreciation and amortization, income tax benefit, interest income, and other income, net.
Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share because to do so would be Anti-dilutive
The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as of the periods presented because to do so would be anti-dilutive:
September 30,
20262025
Shares issuable upon exercise of options to purchase Class A Ordinary Shares18,508,116 14,480,663 
Shares issuable upon exercise of Z33 Series Seed Preferred Shares Put Right— 2,000,000 
Shares issuable upon vesting of restricted share units256,642 573,282 
Restricted share awards124,999 249,997 
Total18,889,757 17,303,942